Hikma Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Hikma Pharmaceuticals Il CEO è Riad Mishlawi, nominato in Sep2023, e ha un mandato di 1.17 anni. la retribuzione annua totale è $ 1.55M, composta da 21.5% di stipendio e 78.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.06% delle azioni della società, per un valore di £ 2.39M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.2 anni e 5.4 anni.

Informazioni chiave

Riad Mishlawi

Amministratore delegato

US$1.6m

Compenso totale

Percentuale dello stipendio del CEO	21.5%
Mandato del CEO	1.2yrs
Proprietà del CEO	0.06%
Durata media del management	1.2yrs
Durata media del Consiglio di amministrazione	5.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Riad Mishlawi rispetto agli utili di Hikma Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	US$285m
Mar 31 2024	n/a	n/a	US$238m
Dec 31 2023	US$2m	US$333k	US$190m

Compensazione vs Mercato: La retribuzione totale di Riad ($USD 1.55M ) è inferiore alla media delle aziende di dimensioni simili nel mercato UK ($USD 3.25M ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Riad con le performance aziendali.

AMMINISTRATORE DELEGATO

Riad Mishlawi (60 yo)

1.2yrs

Mandato

US$1,552,833

Compensazione

Mr. Riad Ali Mishlawi serves as Chief Executive Officer of Hikma Pharmaceuticals PLC since September 01, 2023 and serves as its Director since September 01, 2023. He had been the President of Injectables s...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Said Samih Darwazah	Executive Chairman	17.3yrs	US$3.57m	0.38% £ 15.3m
Riad Mishlawi	CEO & Director	1.2yrs	US$1.55m	0.060% £ 2.4m
Mazen Samih Darwazah	Executive Vice Chairman & President of MENA	19.2yrs	US$2.84m	0.63% £ 25.0m
Khalid Waleed Al Nabilsi	Chief Financial Officer	13.8yrs	Nessun dato	0.20% £ 8.1m
Patricia Bousfield	Chief Information Officer	no data	Nessun dato	Nessun dato
Guy Featherstone	Associate Director of Investor Relations	no data	Nessun dato	Nessun dato
Samuel Park	General Counsel	no data	Nessun dato	Nessun dato
Bassam Wael Kanaan	Executive Vice President of Corporate Development and M&A	10.7yrs	Nessun dato	0.26% £ 10.3m
Hussein Arkhagha	Chief People Officer	1.2yrs	Nessun dato	Nessun dato
Susan Ringdal	Executive Vice President of Strategic Planning & Global Affairs	6.8yrs	Nessun dato	Nessun dato
William Larkins	President of Injectables Business	1.2yrs	Nessun dato	Nessun dato
Julie Hill	Senior Vice President of Corporate Quality Compliance/Health & Safety	less than a year	Nessun dato	Nessun dato

1.2yrs

Durata media

60yo

Età media

Gestione esperta: Il team dirigenziale di HIKL non è considerato esperto (durata media 1.2 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Said Samih Darwazah	Executive Chairman	17.3yrs	US$3.57m	0.38% £ 15.3m
Riad Mishlawi	CEO & Director	1.2yrs	US$1.55m	0.060% £ 2.4m
Mazen Samih Darwazah	Executive Vice Chairman & President of MENA	19.2yrs	US$2.84m	0.63% £ 25.0m
Victoria Hull	Senior Independent Non-Executive Director	2yrs	US$149.27k	Nessun dato
Mary Henderson	Independent Non-Executive Director	8.1yrs	US$176.38k	0.0032% £ 127.3k
John Castellani	Independent Non-Executive Director	8.7yrs	US$159.69k	0.0016% £ 62.9k
Mohammed Ali Khaldoun Al-Husry	Non-Executive Director	19.1yrs	US$116.72k	0.52% £ 20.9m
Douglas Hurt	Independent Non-Executive Director	4.5yrs	US$149.85k	0.0020% £ 80.8k
Deneen Vojta	Independent Non-Executive Director	2yrs	US$127.05k	0.00045% £ 17.9k
Cynthia Flowers	Independent Non-Executive Director	5.4yrs	US$134.68k	0.00050% £ 19.9k
Nabil Rizk	Chairman of West-ward Pharmaceuticals	no data	Nessun dato	Nessun dato
Laura Balan	Independent Non-Executive Director	2.1yrs	US$124.98k	Nessun dato

5.4yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di HIKL sono considerati esperti (durata media dell'incarico 5.4 anni).

Hikma Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Hikma Pharmaceuticals PLC Announces Executive Changes

Hikma Pharmaceuticals PLC, Annual General Meeting, Apr 25, 2024

Hikma Pharmaceuticals PLC Announces Company Secretary Change

Insider recently sold UK£543k worth of stock

Hikma Pharmaceuticals PLC Appoints Bill Larkins as President of Its Injectables Business, Effective 1 September 2023

Hikma Pharmaceuticals PLC Appoints Deneen Vojta as Director

Recent updates

Hikma Pharmaceuticals plc Announces the Shelf-Life Extension of KLOXXADO Nasal Spray 8mg from 24 to 36 Months

Hikma Pharmaceuticals PLC Revises Group Earnings Guidance for the Full Year of 2024

Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024

Hikma Pharmaceuticals PLC Announces Executive Changes

Upcoming dividend of US$0.47 per share

Now 21% undervalued

Final dividend of US$0.47 announced

Full year 2023 earnings released: EPS: US$0.86 (vs US$0.84 in FY 2022)

Hikma Pharmaceuticals PLC, Annual General Meeting, Apr 25, 2024

Hikma Announces US Launch of COMBOGESIC IV

Now 22% undervalued after recent price drop

Hikma Pharmaceuticals PLC Announces Company Secretary Change

Hikma Pharmaceuticals PLC to Report First Half, 2024 Results on Aug 08, 2024

Hikma Pharmaceuticals PLC Provides Earnings Guidance for the Year 2023

Hikma Pharmaceuticals PLC(LSE:HIK) dropped from FTSE 250 Index

Now 21% undervalued

New minor risk - Insider selling

Insider recently sold UK£543k worth of stock

Hikma Pharmaceuticals PLC Appoints Bill Larkins as President of Its Injectables Business, Effective 1 September 2023

First half 2023 earnings released: EPS: US$0.59 (vs US$0.76 in 1H 2022)

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Hikma Exceeds 150 Injectable Medicines in the US with Launch of Dobutamine Injection, USP

Now 21% undervalued

Upcoming dividend of US$0.37 per share at 2.7% yield

Full year 2022 earnings released: EPS: US$0.84 (vs US$1.82 in FY 2021)

Hikma Launches Authorized Generic of Xyrem® (Sodium Oxybate) in the US

Hikma Pharmaceuticals PLC to Report Fiscal Year 2022 Results on Feb 23, 2023

Hikma Pharmaceuticals PLC Appoints Deneen Vojta as Director

Hikma Pharmaceuticals PLC Announces Board Appointments

Investor sentiment improved over the past week

Hikma Pharmaceuticals PLC(LSE:HIK) dropped from FTSE 100 Index

Hikma Pharmaceuticals PLC and Glenmark Specialty S.A., Launches RYALTRIS in US

Upcoming dividend of US$0.19 per share

First half 2022 earnings released

Hikma Pharmaceuticals plc Recommends Interim Dividend, Payable on 19 September 2022

Insufficient new directors

Insufficient new directors

Hikma Pharmaceuticals plc Announces Company Secretary Change

Hikma Pharmaceuticals PLC Announces Chief Executive Officer Changes

Hikma Pharmaceuticals PLC Approves Final Dividend for the Year 2021

Hikma Pharmaceuticals PLC (LSE:HIK) completed the acquisition of Custopharm Inc. from Water Street Healthcare Partners, LLC.

Upcoming dividend of US$0.36 per share

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Hikma Pharmaceuticals PLC (LSE:HIK) announces an Equity Buyback for £300 million worth of its shares.

Hikma Pharmaceuticals PLC Provides Revenue Guidance for 2022

Hikma Pharmaceuticals PLC (LSE:HIK) completed the acquisition of Canadian assets of Teligent Inc from Teligent, Inc. (OTCPK:TLGT.Q).

Hikma Pharmaceuticals PLC (LSE:HIK) agreed to acquire Canadian assets of Teligent Inc. from Teligent, Inc. (OTCPK:TLGT.Q) for $45.7 million.

Hikma Pharmaceuticals PLC (LSE:HIK) agreed to acquire Custopharm Inc. from Water Street Healthcare Partners, LLC for approximately $430 million.

Upcoming dividend of US$0.18 per share

First half 2021 earnings released: EPS US$1.07 (vs US$0.88 in 1H 2020)

Hikma Pharmaceuticals PLC Announces US FDA Approval of KLOXXADO

New 90-day low: UK£22.38

Full year 2020 earnings released: EPS US$1.83 (vs US$2.01 in FY 2019)

Revenue beats expectations

Hikma Pharmaceuticals PLC, Annual General Meeting, Apr 23, 2021

Eyevance Pharmaceuticals Expands U.S. Promotion of ZERVIATE® In Agreement with Hikma

Hikma Pharmaceuticals PLC to Report Fiscal Year 2020 Results on Feb 25, 2021

Hikma Pharmaceuticals PLC (LSE:HIK) entered into a non-binding term sheet to acquire 91.2% stake in GlaxoSmithKline S.A.E (CASE:BIOC) from Glaxo Group Limited.

New 90-day low: UK£24.23

Hikma Pharmaceuticals PLC Provides Update on Generic Advair Diskus®

Hikma Pharmaceuticals PLC Launches Generic Advair Diskus®

New 90-day low: UK£24.51

Amarin Corporation plc Files Patent Infringement Lawsuit Against Hikma Pharmaceuticals PLC and Hikma’s U.S. affiliate

Hikma Pharmaceuticals PLC Launches Icosapent Ethyl Capsules 1gm in the US

Hikma Pharmaceuticals plc Announces Board and Committee Changes

Hikma Pharmaceuticals PLC and Arecor Limited Expand Collaboration with New Agreement to Develop and Commercialize Ready-To-Administer Medicine

Hikma Pharmaceuticals PLC Updates on ANDA for Generic Advair Diskus

Hikma Pharmaceuticals PLC to Report November,2020 Results on Nov 05, 2020